Project CBD
MARCH 21, 2023
Auditory & Other Symptoms The survey, whose findings were published in February 2023 in the Journal of Otolaryngology – Head & Neck Surgery 1 evaluated cannabis perceptions and consumption among 45 adult tinnitus patients randomly selected and recruited from an outpatient ear, nose, and throat clinic in Ontario, Canada.
Veriheal
JANUARY 26, 2023
Using Cannabis for Bipolar Disorder Symptoms Is Also Supported by Early Research Earlier groundbreaking research has also suggested cannabis consumption may be associated with improved bipolar disorder symptoms for patients. Thus, this groundbreaking study laid the foundation for understanding how cannabinoids can support mental health.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
TheAnswerPage
MAY 3, 2021
There is a high concentration of CB1 receptors in the areas of the brain that control food intake and satiety, and these findings suggest that there is an association between marijuana consumption and appetite regulation. Cannabis sativa and the endogenous cannabinoid system: therapeutic potential for appetite regulation. Int.J.Obes.(Lond).
Veriheal
JANUARY 10, 2023
In 2006, Judge Gladys Kessler oversaw a case against tobacco companies presented by the American Cancer Society and others. What’s in cannabis: Over 100 cannabinoids. The terpenes, cannabinoids, flavonoids, vitamins, minerals, and amino acids found in cannabis have beneficial properties. Now they’re around $10.
Cannabis Law Report
JANUARY 23, 2022
This brings us to one of the most powerful medical studies that demonstrate the therapeutic potential of cannabinoids. CBD was also well tolerated by patients with no severe adverse events due to its consumption being reported. Our strict drug policies have made research cannabinoids and cannabis extremely challenging.
Greencamp
AUGUST 16, 2018
Exploring the available research on ALS and cannabinoids. The CBD cannabinoid is proven to be an exceptional seizure-controlling agent for epilepsy patients, and also shows great promise for treating Parkinson’s , Alzheimer’s and Multiple Sclerosis. The first study I will reference is from 2006, conducted on mice.
Greencamp
JANUARY 5, 2019
“An involvement of the endocannabinoid system with schizophrenia is supported both by the epidemiological observation that increased cannabis use is associated with a heightened risk for schizophrenia and that acute consumption of cannabis or synthetic cannabinoids can elicit psychotic symptoms in susceptible individuals.”.
Expert insights. Personalized for you.
144 
Let's personalize your content